Analysis of serum neutralizing antibodies in patients with COVID-19 and its clinical significance

doi:10.19871/j.cnki.xfcrbzz.2023.02.007

Abstract

Abstract: Objective To analyze the levels of neutralizing antibody in the serum of patients infected with SARS-CoV-2,and to evaluate the severity and prognosis. Method In this study, 172 COVID-19 patients who underwent isolation treatment at Shijiazhuang Fifth Hospital from February 2020 to March 2021 were selected, serum samples were collected from COVID-19 patients, including patients with early(1-7d), intermediate(8-14d), late(15-21d), and recovery(22-41d) stages of infection. The levels of SARS-CoV-2 neutralizing antibody were detected by magnetic particle-based chemiluminescence immunoassay. Result The positive rates of neutralizing antibody increased gradually with disease progression, peaking at 90% in the late stage of infection.The levels of SARS-CoV-2 neutralizing antibody were positively corrected with the length of infection(R=0.35, P<0.001). In early stage,the positive rates of neutralizing antibody were significantly higher in the asymptomatic infected persons than in the symptomatic patients (P<0.05), and the positive rates and levels of neutralizing antibody were significantly higher in patients <60 years old than in patients ≥60 years old.In the late and recovery stages, the positive rates and levels of neutralizing antibody increased gradually with disease progression (P<0.001),and were not correlated with age. Conclusion The positive rates and levels of SARS-CoV-2 neutralizing antibody in serum were related with the severity of COVID-19 patients, and maybe an indicator for evaluating the prognosis.

Key words: Coronavirus disease 2019, Severe acute respiratory syndrome coronavirus 2, Neutralizing antibody, Magnetism microparticulate chemiluminescence

CLC Number:

R511

Xu Yi, Xu Heng, Guo Yun, Huang Ying, Gao Peng, Hu Qian, Gao Huixia. Analysis of serum neutralizing antibodies in patients with COVID-19 and its clinical significance[J]. Electronic Journal of Emerging Infectious Diseases, 2023, 8(2): 34-38.

References

[1] LING N, FANG Y, MENGLC. Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals[J]. Immunity, 2020, 52(6):971-977.
[2] 张茜, 冯振卿. 新型冠状病毒肺炎的抗体应对策略[J]. 南京医科大学学报(自然科学版),2020,40(2):155-159.
[3] MARKUS H, HANNAH KW, SIMON S, et al.SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor[J]. Cell, 2020, 181(2):271-280.
[4] WALLS AC, PARK YJ, TORTORICI MA, et al.Structure, function,and antigenicity of the SARS-CoV-2 spike glycoprotein[J]. Cell, 2020, 181(2):281-292.
[5] ZHOU P, YANG XL, WANG XG, et al.A pneumonia outbreak associsted with a new coronavirus of probable batorigin[J]. Nature, 2020, 579(7798):270-273.
[6] 周阳春, 丁世家, 唐彦, 等. 建立磁微粒化学发光免疫分析法检测血清CTX[J]. 国际检验医学杂志, 2020, 41(18):2236-2238.
[7] 国家中医药局综合司, 国家卫生健康委员会办公厅. 关于印发新型冠状病毒感染诊疗方案(试行第十版)的通知[EB/OL]. http://www.gov.cn/zhengce/.
[8] SARA A, YOUSEF F, MAHDI Z, et al.COVID-19:Significance of antibodies[J]. Hum Antibodies, 2020, 28(4):287-297.
[9] LARRY LL, BRETT PR, DANIEL KJ.Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID-19 Patients[J]. J Clin Microbiol, 2020,58(12):1-14.
[10] 郝鹏飞, 许汪, 杜寿文, 等. 冠状病毒起源、受体及新型冠状病毒检测与疫苗最新研究进展[J/CD]. 新发传染病电子杂志, 2020, 5(2):74-78.
[11] SURYADEVARA N, SHRIHARI S, GILCHUK P, et al.Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein[J]. Cell, 2021, 184(9):2316-2331.
[12] WU Y, WANG F, SHEN C, et al.A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2[J]. Science, 2020, 368(6496):1274-1278.
[13] EAMON OM, PAULA B, KIERAN AW.Immune response following infection with SARS-CoV-2 and other coronaviruses:A rapid review[J]. Rev Med Virol, 2021, 31(2):1-11.
[14] 李幸乐, 卢世栋, 李金月, 等. 新型冠状病毒肺炎病例血清中和抗体动态变化及影响因素[J]. 中华实验和临床病毒学杂志, 2021, 35(3):341-344.
[15] 王俊, 何兰, 陈晴晴, 等. 43例新型冠状病毒肺炎患者血清抗体动态检测结果分析[J]. 中国病原生物学杂志, 2021, 16(10):1143-1147.
[16] BERISLAV B, SASKIA CS, STEFANIE W.Low serum neutralizing anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods[J]. Cell Mol Immunol, 2021, 18(4):936-944.
[17] FAN W, MEI L, AOJIE W.Evaluating the Association of Clinical Characteristics With Neutralizing Antibody Levels in Patients Who Have Recovered From Mild COVID-19 in Shanghai,China[J]. JAMA Intern Med, 2020,180(10):1356-1362.
[18] QING L, HOU HY, CAI ZY, et al.Kinetics of Neutralizing Antibody Response Underscores Clinical COVID-19 Progression[J]. J Immunol Res, 2021:9822706.